• Publications
  • Influence
Adult and paediatric poor metabolisers of desloratadine: an assessment of pharmacokinetics and safety
TLDR
It is demonstrated that the increased exposure in poor metabolisers is independent of age when administered at age-appropriate doses and not associated with any changes in the safety and tolerability profile of desloratadine, including cardiovascular safety. Expand
Dose-ranging study of mometasone furoate dry powder inhaler in the treatment of moderate persistent asthma using fluticasone propionate as an active comparator.
TLDR
A total daily doses of 400 microg of MF-DPI provides clinical benefit comparable to that observed with a total daily dose of 500microg of FP Diskhaler, while a totaldaily 800-microg dose of MF -DPI conferred no significant additional benefit. Expand
Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. The 194-079 Study Group.
TLDR
Overall, mometasone furoate was at least as effective as fluticasone propionate at equivalent doses and adequately controlled symptoms of perennial rhinitis and were well tolerated. Expand
Once‐daily mometasone furoate aqueous nasal spray (Nasonex®) in seasonal allergic rhinitis: an active‐ and placebo‐controlled study
TLDR
It was concluded that mometasone furoate adequately controls symptoms of moderate to severe seasonal allergic rhinitis, offers the advantage of OD treatment, and is well tolerated. Expand
Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients.
TLDR
Mometasone furoate nasal spray adequately controls symptoms of perennial allergic rhinitis, offers the advantage of once daily treatment, and is well tolerated. Expand
Desloratadine therapy for symptoms associated with perennial allergic rhinitis.
TLDR
These results confirm and extend previous findings that desloratadine is safe and is associated with a statistically significant reduction in nasal and nonnasal symptoms in patients with PAR. Expand
Comparison of the efficacy and safety of mometasone furoate dry powder inhaler to budesonide Turbuhaler.
TLDR
A total daily dose of 400 microg of mometasone furoate administered by dry powder inhaler provides a well-tolerated treatment for patients with moderate persistent asthma and results in a significantly greater improvement, when compared to a daily doses of 800 microg BUD Turbuhaler in the parameters measured in this study. Expand
Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. 194-079 Study Group.
TLDR
Overall, mometasone furoate was at least as effective as fluticasone propionate at equivalent doses and adequately controlled symptoms of perennial rhinitis and were well tolerated. Expand
Assessment by Nasal Biopsy of Long-Term Use of Mometasone Furoate Aqueous Nasal Spray (Nasonex) in the Treatment of Perennial Rhinitis
TLDR
It is demonstrated that long-term administration of mometasone furoate is not associated with adverse tissue changes in the nasal mucosa of patients with perennial rhinitis. Expand
Comparison of once-daily to twice-daily treatment with mometasone furoate dry powder inhaler.
TLDR
Once-daily dosing with an effective inhaled corticosteroid would likely enhance compliance and, therefore, aid in the management of asthma and offers an effective and convenient treatment that could aid compliance in the treatment of asthma. Expand
...
1
2
3
4
5
...